Esculetin promotes type I procollagen expression in human dermal fibroblasts through MAPK and PI3K/Akt pathways.

Molecular and Cellular Biochemistry
Jung Hae ParkJeong A Han

Abstract

Type I collagen is the major constituent of the skin and the reduction of dermal type I collagen content is closely associated with the intrinsic skin aging. We here found that esculetin, 6,7-dihydroxycoumarin, strongly induces type I procollagen expression in human dermal fibroblasts. Esculetin not only increased protein levels of type I procollagen but also increased mRNA levels of COL1A1 but not COL1A2. Esculetin activated the MAPKs (ERK1/2, p38, JNK) and PI3K/Akt pathways, through which it promoted the type I procollagen expression. We also demonstrated that the binding motifs for transcription factor Sp1 occur with the highest frequency in the COL1A1 promoter and that esculetin increases the Sp1 expression through the MAPK and PI3K/Akt pathways. These results suggest that esculetin promotes type I procollagen expression through the MAPK and PI3K/Akt pathways and that Sp1 might be involved in the esculetin-induced type I procollagen expression via activation of the COL1A1 transcription.

References

Apr 21, 1999·Current Opinion in Cell Biology·S J LeeversM D Waterfield
Apr 27, 2000·The Journal of Biological Chemistry·W Y ParkS C Park
Nov 7, 2001·The Journal of Clinical Investigation·S A JimenezJ Rosenbloom
Nov 17, 2001·The Journal of Investigative Dermatology·J H ChungH C Eun
Jun 18, 2002·Cancer Letters·Chau Jong WangTsui Hwa Tseng
Sep 5, 2002·Ageing Research Reviews·Laure Rittié, Gary J Fisher
Jun 17, 2003·Biological & Pharmaceutical Bulletin·Takao KanekoFumiyo Takabayashi
May 22, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yoshihide AsanoKunihiko Tamaki
Jul 24, 2004·The Journal of Biological Chemistry·Masatoshi JinninKunihiko Tamaki
Dec 8, 2004·Current Pharmaceutical Design·Konstantina C FylaktakidouDemetrios N Nicolaides
Jul 30, 2005·Toxicology and Applied Pharmacology·Hsing-Chun KuoTsui-Hwa Tseng
Aug 6, 2005·The Journal of Pharmacology and Experimental Therapeutics·Naoko KandaShinichi Watanabe
Nov 23, 2007·Toxicology and Applied Pharmacology·Cheol ParkYung Hyun Choi
Nov 28, 2007·Archives of Pharmacal Research·Bum-Chun LeeJin Tae Hong
Mar 28, 2008·Biochemical and Biophysical Research Communications·Inken Wierstra
Aug 15, 2008·Journal of Dermatological Science·Jongsung LeeDeokhoon Park
Apr 7, 2009·Annual Review of Biochemistry·Matthew D Shoulders, Ronald T Raines

❮ Previous
Next ❯

Citations

Apr 23, 2013·Journal of Asian Natural Products Research·Yu Niu, Qiu-Xia Meng
Jul 11, 2014·The American Journal of Pathology·Ryoichi MoriIsao Shimokawa
Feb 2, 2016·Scientific Reports·Qingran YanQiong Fu
Aug 21, 2015·Progress in Neuro-psychopharmacology & Biological Psychiatry·Sagrario Martín-AragónJuana Benedí
Feb 3, 2015·Phytotherapy Research : PTR·Manikarna DindaParimal Karmakar
Jul 2, 2016·PloS One·Mehrnaz Gharaee-KermaniJill A Macoska
Mar 16, 2019·Non-coding RNA·Mousa G Eissa, Carol M Artlett
May 11, 2019·Journal of Cellular Biochemistry·Jingyong TanJing Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.